No discussion regarding the future is complete unless AI is incorporated. 
In this episode, Konstantina Katcheves of Teva Pharmaceuticals and Sanskriti Thakur of TOWER Capital Group provide their insights on the impact of not only the benefits of the technology but the regulatory challenges and uncertainty surrounding AI.
 
Host
<a href="https://www.linkedin.com/in/lorielliskatz/" rel="ugc noopener noreferrer" target="_blank">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>, Head of Insights, BioSpace
 
Guests
<a href="https://www.linkedin.com/in/konstantina-katcheves-3757236/" rel="ugc noopener noreferrer" target="_blank">Konstantina Katcheves</a>, Senior Vice President, Innovative Medicines Global Business Development and Acquisitions, Teva Pharmaceuticals
<a href="https://www.linkedin.com/in/sanskritithakur/" rel="ugc noopener noreferrer" target="_blank">Sanskriti Thakur</a>, Chairwoman, TOWER Capital

AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.